Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that act as ligandactivated transcription factors. Although prescribed for dyslipidemia and type-II diabetes, PPAR agonists also possess anti-addictive characteristics. PPAR agonists decrease ethanol consumption and reduce withdrawal severity and susceptibility to stress-induced relapse in rodents. However, the cellular and molecular mechanisms facilitating these properties have yet to be investigated. We tested three PPAR agonists in a continuous access two-bottle choice (2BC) drinking paradigm and found that tesaglitazar (PPARa/g; 1.5 mg/kg) and fenofibrate (PPARa; 150 mg/kg) decreased ethanol consumption in male C57BL/6J mice while bezafibrate (PPARa/g/b; 75 mg/kg) did not. We hypothesized that changes in brain gene expression following fenofibrate and tesaglitazar treatment lead to reduced ethanol drinking. We studied unbiased genomic profiles in areas of the brain known to be important for ethanol dependence, the prefrontal cortex (PFC) and amygdala, and also profiled gene expression in liver. Genomic profiles from the non-effective bezafibrate treatment were used to filter out genes not associated with ethanol consumption. Because PPAR agonists are anti-inflammatory, they would be expected to target microglia and astrocytes. Surprisingly, PPAR agonists produced a strong neuronal signature in mouse brain, and fenofibrate and tesaglitazar (but not bezafibrate) targeted a subset of GABAergic interneurons in the amygdala. Weighted gene co-expression network analysis (WGCNA) revealed co-expression of treatment-significant genes. Functional annotation of these gene networks suggested that PPAR agonists might act via neuropeptide and dopaminergic signaling pathways in the amygdala. Our results reveal gene targets through which PPAR agonists can affect alcohol consumption behavior.
et al., 2009). Although PPARb/d is the most abundant isotype in brain, we know the least about its physiological function. Recent evidence suggests that drugs targeting PPARs might be effective in treating drug dependence (for review see Le Foll et al., 2013) . Retinoic acid is the only known RXR ligand and, interestingly, retinoic acid signaling was implicated in acute ethanol responses in mice (Kerns et al., 2005) . Also, pioglitazone and rosiglitazone (PPARg agonists) reduced ethanol consumption in rats (Stopponi et al., 2011 (Stopponi et al., , 2013 . Intracerebroventricular administration of a PPARg antagonist blocked the reduction in ethanol consumption, suggesting that this effect is mediated by central PPARg receptors (Stopponi et al., 2011) . Additionally, pioglitazone and rosiglitazone reduced ethanol withdrawal severity and stressinduced reinstatement of ethanol consumption in dependent rats without altering food or saccharine self-administration (Stopponi et al., 2011) . Clofibrate, a PPARa agonist, prevented acquisition of nicotine dependence in naïve rats and monkeys and decreased nicotine self-administration in nicotine-dependent rats and monkeys (Panlilio et al., 2012) . Thus, in addition to their known usefulness in cardiovascular disease and type II diabetes mellitus (Rosenson et al., 2012) , PPAR agonists might be a potential treatment for alcohol dependence and other addictions.
Based on the evidence for PPARs in regulating ethanol intake in rodents, we assessed the effects of different PPAR agonists on voluntary ethanol consumption in a mouse strain that consumes large amounts of alcohol and examined their effects on gene expression in brain regions important for reducing ethanol consumption. We show that fenofibrate and tesaglitazar decrease ethanol consumption in mice without affecting overall fluid intake, while bezafibrate did not change ethanol consumption. We reasoned that the PPAR treatment-responsive transcript changes in the brain important for reducing ethanol consumption should reflect treatment effectiveness. To the best of our knowledge, this is the first study to demonstrate brain gene expression changes induced by PPAR agonists at doses that decrease alcohol consumption in the amygdala and PFC of mice, two key areas for alcohol dependence.
Methods

Animals
All studies were conducted in adult drug-naïve C57BL/6J (B6) male mice that were purchased at 8 weeks of age from Jackson Laboratories (Bar Harbor, ME). We chose this strain because of their propensity for voluntary ethanol consumption (Belknap et al., 1997) . Seventy-two mice between 8 and 12 weeks old were used: 32 for the ethanol experiment in which mice received ethanol and PPAR agonists or saline (4 groups with 8 mice each) and 40 for the microarray experiment in which mice received PPAR agonists or saline only (4 groups with 10 mice each). Mice were housed in the Animal Resources Center at The University of Texas at Austin with 12-h light/dark cycles (lights on at 10:00 AM) and had ad libitum access to rodent chow (Prolab RMH 180 5LL2 chow, TestDiet, Richmond, IN) and water. All efforts were made to minimize animal suffering, to reduce the number of animals used, and to utilize alternatives to in vivo techniques, if available. All experiments were approved by The University of Texas at Austin Institute for Animal Care and Use Committee and were conducted in accordance with NIH guidelines with regard to the use of animals in research.
Ethanol treatment
We used a two-bottle choice (2BC) voluntary ethanol consumption protocol as previously described (Blednov et al., 2003) .
Briefly, two drinking bottles were continuously available to individually-housed mice. One contained water and the other 15% ethanol (v/v) . Once stable ethanol consumptions were reached, we measured ethanol intake after two days of saline injections and grouped mice (8 mice per group) to provide similar levels of ethanol intake and preference. We administered PPAR agonists or saline depending on their group assignment. We measured consumption (g/kg body weight/24 h) and calculated preference as the amount of ethanol consumed divided by the total amount of fluids consumed per day (a value >50% indicates a preference for ethanol). Data are reported as the mean ± S.E.M. We used the statistics software program GraphPad Prism (Jandel Scientific, Costa Madre, CA) to perform a two-way ANOVA with repeated measurements and Bonferroni post hoc test.
Drugs
The PPARa agonist fenofibrate (feno) (SigmaeAldrich, St. Louis, MO), pan-PPAR agonist bezafibrate (beza) (SigmaeAldrich, St. Louis, MO) and dual PPARaePPARg agonist tesaglitazar (tesa) (Tocris Bioscience, Minneapolis, MN) were freshly prepared as suspensions in saline with 4e5 drops of Tween-80 and injected in a volume of 0.05 ml/10 g of body weight. We administered (p.o.) PPAR agonist (150 mg/kg, 75 mg/kg, or 1.5 mg/kg of feno, beza, and tesa, respectively) or saline for eight days. Doses of drugs and routes of administration were based on published biological activity in vivo. Tesa was only delivered for six days in the 2BC experiment because its decreased effect on ethanol drinking behavior plateaued at that time-point.
Tissue collection
Twenty-four hours after administration of the last PPAR agonist for the microarray study, mice were euthanized by cervical dislocation. Livers were removed and brains were placed in a Petri dish on ice. After removal of olfactory bulbs, PFC was dissected by cutting the foremost 2 mm of the cortex on each side, at an approximate 50-degree angle from the midline of the brain. Brains were then placed in a coronal Zivic mouse brain slicer with a 0.5 mm resolution (Zivic Instruments, PA), and the amygdala was dissected from slices cut from the following coordinates: coronal level 56e66 [Bregma (À0.18) À (À1.155)] and 66e80 [Bregma (À1.155) À (À2.55)]. Tissue was immediately flash-frozen in liquid nitrogen and stored at À80 C until use. The amygdala and PFC were chosen for their importance in reward signaling and ethanol dependence (Koob and Volkow, 2010) . The liver was chosen in order to validate microarray results since PPAR agonists are known to change liver gene expression (Rogue et al., 2011) .
RNA preparation and microarray hybridization
We extracted RNA using the MagMAX-96 Total RNA Isolation Kit (Life Technologies, Grand Island, NY). Total RNA was quantified on a NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific Inc., Rockford, IL) and assessed for quality using the Agilent TapeStation (Agilent Technologies, Inc., Santa Clara, CA). All samples passed quality control measures (RIN > 8). RNA was amplified and biotinlabeled using the Illumina ® TotalPrepTM RNA Amplification kit (Ambion, Austin, TX), and aliquots of labeled cRNA were sent to the Yale Center for Genome Analysis (West Haven, CT), where they were hybridized to Illumina ® MouseWG-6 v2 Expression BeadChips (Illumina, Inc., San Diego, CA). Each beadchip contains six independent arrays. Samples were counterbalanced to avoid batch effects. The amount of each transcript for each animal was measured by fluorescent intensity after scanning. Microarray data 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 will be deposited in the NCBI Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/) and described in accordance with MIAME guidelines. We have used the Illumina platform frequently in the past with repeated validations using independent qRT-PCR experiments. Correspondence between the microarray and RT-PCR results exceeds 80% Ponomarev et al., 2010 Ponomarev et al., , 2012 .
Microarray data processing
Microarray data were analyzed using R and Microsoft Excel. Each tissue was analyzed separately. Quality assessment of the data using Bioconductor arrayQualityMetrics package (Kauffmann et al., 2009 ) resulted in the removal of 7 outliers: amygdala 16 (fenotreated) and 31 (beza-treated); PFC 6 (tesa-treated) and 36 (fenotreated); and liver 11 (beza-treated), 27 (tesa-treated) and 36 (fenotreated). Liver 11 and 36, amygdala 16 and 31, and PFC 6 and 36 were on a faulty beadchip. Variance stabilization transformation and quantile normalization were used to pre-process the data using the Bioconductor Lumi package (Du et al., 2008) . Groups being compared were normalized together, i.e., saline and beza, saline and tesa, and saline and feno. Lastly, outlier values for each gene within a group were removed using Grubbs' test (p < 0.05). After data processing, the total number of unique genes reliably expressed (i.e., detection p < 0.05 and detected on at least 80% of the samples) in each tissue region for each treatment is provided (Table 1) .
Differential expression analysis
To detect genes differentially expressed between treated and control mice, we used the Bioconductor package Limma to fit a linear model for each gene (Smyth, 2004) . Differential expression analysis produced a top-table, a list of Illumina IDs and their corresponding gene symbols, fold changes (expression level of treated relative to control mice) and p values for the t-test statistic. In order to mitigate the number of false positives but avoid discarding potentially important genes, we used a relaxed statistical significance cut-off value of p < 0.05 (uncorrected) for all analyses in combination with multiple bioinformatics approaches. This technique has been successfully applied in previous studies (Blednov et al., 2012; Miller et al., 2013; Ponomarev et al., 2012; Presson et al., 2008; Rosen et al., 2011; Winden et al., 2011) . In all reported analyses, treatment-regulated genes are those differentially expressed at p < 0.05.
WGCNA
For a systems-level study of the transcriptome, we identified coexpressed genes using weighted gene co-expression network analysis (WGCNA) as described previously . Each tissue region was analyzed separately. All reliably detected genes were included in the network construction, and data from all treatments (feno, tesa, beza and saline) were used to detect coexpression patterns. Signed networks were constructed using R and custom functions available at http://www.genetics.ucla.edu/ labs/horvath/CoexpressionNetwork/. The power was set to b ¼ 11, b ¼ 14 and b ¼ 7 for the amygdala, PFC and liver network, respectively, and minimum module size of 100, 150, and 100 genes for amygdala, PFC and liver, respectively . A dendrogram cut height of 0.99 was used for amygdala and PFC, and 0.995 was used for liver. Gene modules corresponding to branches of the dendrogram were labeled in unique colors. Genes whose profile failed to cluster in the network were labeled in gray. A module was treatment-responsive if it contained more genes with expression changes after PPAR agonist treatment than was expected by chance (hypergeometric p < 0.05).
Functional annotation of genesets
We used several complementary approaches to better understand the global interactions of the gene lists resulting from differential expression analysis and to characterize the treatmentresponsive modules resulting from WGCNA.
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt, http:// www.webgestalt.org/) was used to conduct overrepresentation analysis (ORA) of pathways, gene ontologies, phenotypes and proteineprotein interactions of the top-tables and treatmentresponsive modules. For each list of differentially expressed genes and treatment-responsive modules, all unique genes in the list were submitted to WebGestalt based on gene symbol. The background list for each tissue region consisted of all genes that were used to construct the network.
Top-tables and treatment-responsive modules were further assessed for the overrepresentation of cell-type specific genes. Modules or top-tables that contained more cell-type specific genes than expected by chance (hypergeometric p < 0.05) were designated as enriched for that particular cell-type. Genes were matched by gene symbols. The lists of genes that are preferentially expressed in a particular cell type were from published data. Amygdala and PFC data were queried for the following brain cell types: microglia (Oldham et al., 2008) , oligodendrocytes (Cahoy et al., 2008) , astrocytes (Cahoy et al., 2008) , neurons (Cahoy et al., 2008) , GABAergic neurons (Sugino et al., 2006) and glutamatergic neurons (Sugino et al., 2006) . Liver was queried for liver cell types: Kupffer, hepatocytes and hepatic stellate cells (Takahara et al., 2006) . The list of PPAR targets was curated from the literature and target prediction (downloaded from tfacts.org). The list of ethanolconsumption related genes was curated from mouse gene knockout, gene overexpression and microarray data (found on the INIA IT-GED website at http://inia.icmb.utexas.edu/).
Results
Effect of PPAR agonists on ethanol and water consumption
We tested effects of PPAR agonists on ethanol consumption and preference in continuous 2BC drinking in male C57BL/6J mice. Fig. 1 (left panel) shows the total ethanol consumption over 24 h averaged for days 5 and 6. Feno and tesa decreased ethanol consumption by approximately 50% and 75%, respectively, while beza had no Table 1 Number of unique genes detected on microarrays and differentially expressed in the amygdala, PFC and liver following tesaglitazar, fenofibrate and bezafibrate treatment. The first column displays the number of unique genes detected using the criteria Q1 that the gene must appear on 80% or more of the microarrays in the groups being compared, with a detection p-value cutoff < 0.05. The second column displays the number of unique differentially expressed (DE) genes in the amygdala, PFC and liver after fenofibrate (feno), tesaglitazar (tesa) and bezafibrate (beza) treatment at p < 0.05. (Fig. 1 ). Ethanol preference followed the same pattern as ethanol consumption, and none of the treatments altered total fluid intake ( Fig. 1 ).
Genes differentially expressed by PPAR agonist treatment in mouse amygdala, PFC and liver
We used principle component analysis (PCA) to analyze gene expression values. The amygdala, PFC and liver samples clustered separately, indicating that tissue region was the largest source of variance in the data (Fig. S1A ). Hierarchical clustering (HCL) confirmed the PCA results (Fig. S1B ). Liver samples clustered into two groups: one containing beza and saline samples (not effective for reducing alcohol consumption) and the other containing tesa and feno samples (effective for reducing alcohol consumption) (Fig. S1C) .
Next we performed differential expression analysis to determine the genes that are regulated by each PPAR agonist in the amygdala, PFC and liver. The top-tables (Tables S1eS3) and the number of differentially expressed genes (Table 1) are shown. Fold changes after feno and tesa treatment are modest in brain relative to those in liver. Fold changes after beza treatment are similar across tissues ( Table S4 ). Note that each Illumina ID maps to only one gene, but one gene can map to several Illumina IDs. Thus, it is possible to have the same gene both up-and down-regulated. This could indicate differential regulation of splice-variants or reflect false positives that are expected in whole-genome analyses. In some cases, the number of unique genes in the up-and downregulated groups is thus higher than the total number of unique genes in the top-table.
We assessed cell-type specificity in the up-and down-regulated genes for each treatment by determining if there is an overrepresentation of cell-type specific genes in the regulated gene-sets (Fig. 2) . In the amygdala, each PPAR agonist regulated a large number of genes that are preferentially expressed in neurons (feno and tesa p < 0.002; beza p < 0.02) ( Fig. 2A) . In order to classify potential targeted neurons, we used datasets of genes preferentially expressed in GABAergic and glutamatergic neurons. All treatments down-regulated glutamatergic genes, and feno and tesa (but not beza) up-regulated GABAergic genes in the amygdala ( Fig. 2A) . There was not an overrepresentation of either neuronal subtype in the PFC (Fig. 2B) .
In order to link PPAR agonist-regulated genes with changes in alcohol drinking, we tested the differentially expressed genes for Fig. 1 . PPAR agonists decrease ethanol consumption and preference without changing water intake. Ethanol consumption in grams per kilogram of mouse body weight over a 24-h period averaged for days 5 and 6. We calculated preference as the amount of ethanol consumed divided by the total amount of fluids consumed per day (a value >50% indicates a preference for ethanol). Values are expressed as mean ± S.E.M. N ¼ 8 mice in each group: bezafibrate (pan-PPAR agonist), tesaglitazar (dual PPARa and g agonist) and fenofibrate (PPARa agonist). Overall fluid intake is shown on the far right. Statistical analysis was performed by a two-way ANOVA with repeated measurements and Bonferroni post hoc test. ***p-value < 0.0001 and **p-value < 0.001.
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Fig. 2. PPAR agonists alter gene expression in the amygdala and PFC and produce a strong neuronal signature in the amygdala. The number of genes up-and downregulated by fenofibrate (feno) (N ¼ 9), tesaglitazar (tesa) (N ¼ 9e10) and bezafibrate (beza) (N ¼ 9e10) as compared to saline control (N ¼ 9e10) in the amygdala (A) and PFC (B). The numbers above and below the bars represent numbers of up-and down-regulated genes, respectively. We used lists from previously published data containing genes that are preferentially expressed in certain cell types to examine the cell-type specificity of PPAR agonists and tested for enrichment of genes that are preferentially expressed in astrocytes, microglia, neurons, oligodendrocytes (oligos), glutamatergic neurons and GABAergic neurons. The boxes indicate the cell-types that are overrepresented (hypergeometric p-value < 0.05) in the corresponding gene-set. 4   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66   67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100  101  102  103  104  105  106  107  108  109  110  111  112  113  114  115  116  117  118  119  120  121  122  123  124  125  126  127  128  129  130 NP5538_proof ■ 18 July 2014 ■ 4/11 overlap with a list of genes known to affect alcohol consumption (based on studies of mutant mice). In the amygdala, feno and tesa, but not beza treatment groups, contained more alcohol-related genes than expected by chance (hypergeometric p < 0.007 for feno and tesa; p ¼ 0.46 for beza). We used the non-effective beza treatment to filter out non-related genes and found that genes regulated by both feno and tesa but not beza had a greater number of alcohol-related genes than expected by chance in both the amygdala and PFC (Fig. 3) . These genes have already been experimentally validated and shown to change alcohol consumption, thus supporting our approach of using the non-effective treatment to filter out non-related genes.
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In the liver, tesa treatment produced the most genomic perturbations (Fig. S2A) . As expected, known PPAR targets were enriched for each PPAR agonist treatment in the liver (Fig. S2A ). Overrepresentation analysis (ORA) revealed enrichment of pathways and biological processes related to PPAR signaling, fatty acid metabolism and peroxisome signaling (Fig. S2B ). This corroborates previous data and also serves to validate our microarray experiments. Hepatic stellate cells were the only enriched cell type (other than hepatocytes) in liver genes that were up-regulated by tesa treatment (Fig. S2A) . The hypergeometric p-statistics for the cell-type enrichment analyses for all tissues are provided (Table S5 ).
Detailed gene expression analysis after PPAR agonist treatment
Tesa, feno and beza activate different combinations of PPAR isotypes with varying affinity (Table S6) , and this is expected to produce unique genomic signatures. To understand the relationship between the feno-, tesa-and beza-regulated genes, we evaluated the degree of overlap between the top-tables (Fig. 4) and found that it is greater than expected by chance for all overlapping gene regions (hypergeometric p < 0.05). There are many commonly regulated genes among the three PPAR agonists, but each also regulates a unique set of target genes.
We examined highly enriched categories that are most likely relevant in mediating the effects of the PPAR agonists. In order to emphasize the PPAR agonist-induced pathways and ontologies that might be regulating alcohol consumption, we chose a few genes from each enriched category, giving preference to those genes that have also been shown to be regulated by alcohol in the INIA IT-GED (http://inia.icmb.utexas.edu/).
We used the non-effective treatment as a filter to identify genes that were differentially expressed after feno and tesa but not beza treatment. There were 424 genes in this category in the amygdala and 467 in the PFC, and Table 2 highlights the top 20 up-and downregulated genes in these key gene-sets. In general, if a transcript was changed by both feno and tesa, the change was in the same direction, especially in the amygdala.
The 424 genes regulated by feno and tesa in the amygdala are enriched for genes involved in synaptic transmission (e.g., Gabrg1, Abat and Bdnf) and dopaminergic synaptic transmission (e.g., Pmch, Drd1a, Ddc, Ppp1r1b and Crhbp). There was also an upregulation of genes involved in anxiety-related responses (e.g., Npy, Tac1, Pdyn, Drd1a, Pde1b and Grm8).
In addition to the relationship of treatment-regulated genes within a single region, we were interested in the relationship of treatment-regulated genes between regions (Fig. S3) . The degree of overlap was greater than expected by chance between the amygdala and PFC for all three treatments (hypergeometric p < 0.05), suggesting that PPAR agonists differentially regulate genes in the brain versus the liver. Forty-one genes were regulated by both feno and tesa in both brain areas, including many genes involved in synaptic transmission (e.g., Nell2, Ppp2r5d, Rasgrf1, Syt1, Syn3, B3gat1, Sv2b, Sh3kbp1, Crhbp and Cldn5).
Systems level analysis of transcriptional organization using WGCNA
To gain a systems-level understanding of the transcriptome, we used WGCNA to build gene co-expression networks for each tissue region. It is thought that genes that co-express and co-vary perform similar biological functions or act in the same biological pathway ("guilty by association" principle) (Lee et al., 2010) . WGCNA is a complementary approach to differential expression and provides a reference for interpretation and validation of differential expression analysis. We identified the geneegene regulatory relationships that were activated by PPAR agonists, which we refer to as treatment-responsive modules. This approach has been validated by several independent research groups as a method for predicting genes that underlie a biological or molecular process (Horvath et al., 2006; Mulligan et al., 2011; Oldham et al., 2008; Saris et al., 2009; Torkamani et al., 2010; Winden et al., 2009 ).
The networks for amygdala (Fig. 5A) , PFC ( Fig. 5B) and liver ( Fig. S2C) are displayed as dendrograms. Results from cell-type enrichment analyses for treatment-responsive modules are displayed in a column adjacent to the dendrogram. The p values from these analyses can be found in Tables S10 and S11 for amygdala and PFC, respectively. The arrows indicate the direction of fold-change induced by the PPAR agonist for the PPAR agonist-regulated genes in that module. Fig. 3 . Genes implicated in alcohol consumption (from mutant mouse studies) that are in PPAR agonist-regulated genesets in the amygdala and PFC. The diagrams show the alcoholrelated genes regulated by PPAR agonists in the amygdala (left) and PFC (right). Genes were determined to be alcohol-related if mice lacking or over-expressing that gene showed differences in alcohol consumption compared to wild-type mice. Genes regulated by fenofibrate (feno) only, tesaglitazar (tesa) only, and both feno and tesa are shown on the left, right, and center of each diagram, respectively, excluding those genes also regulated by the ineffective bezafibrate treatment . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 We identified 24 out of 39 modules that were treatmentresponsive in the amygdala. The majority of genes clustered into co-expressed modules with only 1352 out of 19,783 genes in the gray category (i.e., expression profiles that failed to cluster). Six modules were responsive to both working treatments. The upregulated treatment-responsive modules (green yellow, orange and dark red) were enriched with known neuronal and GABAergic genes (Table S11) , corroborating the cell-type enrichment analysis of the tesa-and feno-regulated genesets from DE. About half of the co-expressed GABAergic genes were also up-regulated by feno and tesa; for example, Slc32a1, the GABA vesicular transporter was upregulated 29% by feno and 24% by tesa and Abat, the enzyme responsible for catabolism of GABA into succinic semialdehyde was up-regulated 16% for feno and 13% for tesa. We tested the upregulated modules for overlap with a list of genes known to affect alcohol consumption (based on studies of mutant mice), and found that two of these modules contained more alcohol consumptionrelated genes than expected by chance (hypergeometric p < 0.01). Over half of the co-expressed alcohol consumption-related genes were also regulated by feno and tesa; for example, Pdyn (upregulated 23% by feno and 24% by tesa), Penk1 (up-regulated 34% by feno and 49% by tesa) and Ppp1r1b (up-regulated 34% by feno and 67% by tesa) modulate alcohol consumption and are changed (in a coordinated manner) by feno and tesa.
Webgestalt identified G-protein coupled receptor signaling pathways and neuro-active ligand receptor interaction pathways that were enriched in the up-regulated modules. Genes involved in neuropeptide signaling, neuropeptide receptor binding and neuropeptide hormone activity were also prominent. Study of the proteineprotein interactions (PPI) identified several networks in the up-regulated modules, including adenylate cyclase activity and regulation of transcription processes. Genes critical for synaptic transmission dominated the up-regulated modules, including genes coding for ion channels such as voltage-gated potassium, calcium and sodium channels and GABA and glycine receptors.
The down-regulated treatment-responsive modules in the amygdala (salmon, white and dark olive green) were enriched for neuronal and glutamatergic genes (Table S11 ). The salmon module was also enriched for astrocytic and microglial genes. The downregulated modules in the amygdala contained a large PPI network that included 76 genes in the glutamate receptor signaling pathway. Genes involved in cell surface receptor activity, including ion channel activity and tyrosine kinase signaling activity, were also prominent here.
We identified 20 out of 35 modules that were treatmentresponsive in the PFC with 4853 out of 19,400 genes in the gray category. Three modules (green, tan and blue) were responsive to both working treatments (Table S11) and were enriched for genes that are up-regulated by feno and down-regulated by tesa. This is in contrast to the amygdala where the treatment-responsive modules were enriched for feno-and tesa-regulated genes with the same direction of fold change. Two of the three modules were enriched with neuronal genes. We found PPI networks related to glutamate signaling pathways in two of the three modules, and glutamate receptor activity ontologies were enriched in all three treatmentresponsive modules. Families of genes that were enriched included those involved in synaptic transmission (e.g., Kcna1, Kcnd2, Kcnj12, Scn3a, Cacna2d1, Gabrb2, Itpr1, Trpc1), especially as it pertains to learning (long-term depression), mostly due to the coordinated regulation of many glutamate receptors (e.g., Grm7, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 66 Table 2 The top 20 up-and down-regulated genes differentially expressed after treatment with tesaglitazar and fenofibrate but not bezafibrate. Gene expression was measured in the amygdala and PFC after treatment with fenofibrate (feno), tesaglitazar (tesa) or bezafibrate (beza). The table displays the top 20 genes altered by feno and tesa but not beza, with the highest and lowest fold change (FC) (treated versus saline control) in the amygdala and PFC. The fold change values for feno and tesa are displayed in columns 3 and 4, respectively (for the up-regulated genes) and columns 7 and 8, respectively (for the down-regulated genes). The beza fold change is not displayed since these genes were not regulated by beza (i.e., p-value > 0.05). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Gria1, Gria3, Grid2, Grin1). One module (tan) was enriched with genes known to be important for alcohol consumption (Bdnf, Ccnd2, Gabrb2, Gnas, Grin2a and Grm5) with a hypergeometric p < 0.02.
Gene name
Discussion
PPARs are nuclear hormone receptors that act as ligandactivated transcription factors. PPAR agonists are antiinflammatory, neuroprotective, hepatoprotective and have antiaddictive properties (Bordet et al., 2006; Fischer et al., 2003; Panlilio et al., 2012; Stopponi et al., 2011) . Little is known about the mechanisms underlying their CNS effects; thus, we used an unbiased genomic approach to characterize expression profiles in amygdala and PFC by two PPAR agonist treatments that are effective (feno and tesa), and one that is not effective (beza), in reducing alcohol consumption. The transcriptomes were examined using several bioinformatic approaches, including differential expression analysis and WGCNA. All transcripts were analyzed simultaneously, providing a detailed molecular phenotype of brain responses following activation of the PPAR signaling pathway. A dataset of expression levels for most genes in the mouse genome has been made publicly available in Gene Expression Omnibus. This profile will also aid researchers studying other brain diseases that are responsive to PPAR agonists (Alzheimer's, Parkinson's, and Huntington's disease, ischemic brain injury, and schizophrenia), and help define neural mechanisms (and therefore potential treatment) of several CNS diseases.
We demonstrate that tesaglitazar and fenofibrate decrease alcohol consumption in male C57BL/6J mice in a 2BC paradigm.
Tesaglitazar and fenofibrate predominantly activate PAPRa and g and PPARa, respectively (Ljung et al., 2002; Willson et al., 2000) . Consistent with our results for tesaglitazar, other PPARg agonists (pioglitazone and rosiglitazone) decreased alcohol consumption in a 2BC paradigm in rats (Stopponi et al., 2011 (Stopponi et al., , 2013 . However, different effects of PPARa agonists on alcohol consumption have been reported. Consistent with our results for fenofibrate, Barson et al. (2009) found that the PPARa agonist gemfibrozil (50 mg/kg i.g.) decreased voluntary alcohol consumption in male Sprague Dawley rats in a 2BC test using 7% alcohol (Barson et al., 2009 ). However, Schlicht (1987) reported that clofibrate (0.5% diet, approximately 300 mg/kg/day) increased voluntary alcohol consumption in male spontaneous hypertensive rats in a 2BC paradigm using 30% alcohol (Schlicht, 1987) . These conflicting results may be due to the different experimental parameters, including differences in drugs, dosages, rat strains and ethanol concentrations.
Bezafibrate (a/b, d/g agonist) did not decrease alcohol consumption in our study. There are a few considerations that might account for this. b/d activation might oppose or prevent action at a and g subunits. Testing a PPAR agonist with specificity for b/d will be necessary to help determine why bezafibrate was not effective.
Furthermore, it should be noted that a/b/g isotypes function as a triad, and b/d regulates the expression level and activity of PPARa and g (Aleshin et al., 2013) , making it difficult to determine the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 role of a single PPAR isotype in alcohol drinking behavior following bezafibrate treatment. Finally, it is important to consider the doses of the drugs used for our studies. We compared the drug dosages in two ways: 1) in comparison to the human dose calculated as mg/body surface area, a validated measure for humanemouse comparisons (Reagan-Shaw et al., 2008) and 2) as a ratio of dose to the half maximal effective concentration (EC50) required for subtype-specific action (Ljung et al., 2002; Willson et al., 2000) (Table S6 ). Fenofibrate and tesaglitazar were used at about 5e7 times the human dose whereas bezafibrate was equivalent to the human dose. We did not use higher doses of bezafibrate because liver changes in mice have been reported with 20 mg/kg body weight (Knapik-Czajka, 2013) . The dose/EC50 ratio shows that fenofibrate has selectivity for PPARa (8.3) over g (0.6), and tesaglitazar has selectivity for g (6) over a (0.05). In contrast, the ratios for bezafibrate are lower for all three PPARs (0.8 for a, 1.4 for g and 0.7 for b/d) (Table S6 ). It is possible that the dose of bezafibrate used provided less activation of PPARs, possibly accounting for its weaker effects.
PPAR agonists induced both up-and down-regulated genes in the amygdala, PFC and liver. Many of these genes have not been previously implicated in PPAR actions, including some that are regulated by all three PPAR agonists in multiple tissues and contain a PPAR response element in the promoter region (e.g., Dbp, Gm129 and Tsc22d3). Therefore this study reveals potentially novel PPAR agonist targets which may be relevant for other pathological conditions. Because bezafibrate is a pan-PPAR agonist, we expected it to produce the greatest number of gene expression changes, especially considering that the PPARb/d subunit is the most abundant isotype in brain (Moreno et al., 2004) . However, beza produced the fewest expression changes in all tissues studied, while feno produced the most changes in amygdala and PFC, and tesa produced the most changes in liver. These findings are consistent with the behavioral results showing that bezafibrate was ineffective while fenofibrate and tesaglitazar decreased alcohol consumption.
Cell-type enrichment analysis of the differentially expressed genes indicates that the effective treatments (feno and tesa) target a subset of GABAergic interneurons in the amygdala that beza does not. Results from WGCNA show that GABAergic signaling is regulated in a coordinated manner by feno and tesa in the amygdala. The change in expression of GABA neurons is consistent with longstanding evidence for the GABAergic system in alcohol actions (Tabakoff and Hoffman, 2013) . A potential increase in GABAergic signaling resulting from expression changes of multiple GABArelated transcripts could play a role in the anticonvulsant properties of PPAR agonists (Porta et al., 2009; Puligheddu et al., 2013) and the ability of these drugs to suppress alcohol withdrawal signs (Stopponi et al., 2011) .
WGCNA identified several coordinately-expressed groups of genes (modules) that were treatment-responsive. Six modules in the amygdala and three in the PFC were responsive to both effective treatments (feno and tesa). The direction of change for the fenoand tesa-regulated genes is in the same direction for amygdala (but not for PFC), suggesting that the expression changes in amygdala are more crucial for mediating decreased ethanol consumption at the time point analyzed. In the amygdala, many of the differentially expressed (up-regulated) neuropeptide signaling genes were also coordinately regulated by feno and tesa, respectively, as follows: Avp (46%; 52%), Pdyn (23%; 24%), Penk1 (34%; 49%), Tac1 (49%; 48%), Tac2 (16%; 12%), Scg2 (47%; 29%), Gnas (7%; 6%), Npy (6%; 7%) and Pmch (8%; 7%). There were 14 other neuropeptide genes that were co-expressed in the same module, but not significantly regulated by feno and tesa. Neuropeptide signaling in the amygdala has established roles in stress/anxiety and alcohol drinking behavior. Pioglitazone and rosiglitazone (PPARg agonists) demonstrated anti-depressant-like effects in rodents (Ahmed et al., 2010; Sadaghiani et al., 2011) and rosiglitazone reduced physiological responses to psychological stress in rats (Ryan et al., 2012) . This evidence, in combination with our gene expression results, suggests that the role of PPAR agonists in stress/anxiety response might be important for their effects on ethanol consumption and is a promising area of study.
Dysregulation of the dopaminergic system has been linked to addiction (George et al., 2012) . In our study, several components of dopaminergic transmission in the amygdala were up-regulated by feno and tesa, respectively, as follows: Pmch (8%; 6%), Drd1a (32%; 32%), Drd2 (7%; 20%), Ddc (28%; 11%), Ppp1r1b (34%; 67%), Rasd2 (18%; 19%), Rgs9 (38%; 65%) and Slc10a4 (13%; 17%). Furthermore, WGCNA revealed that all of these genes were co-expressed in the same module (green yellow), which was responsive to the effective treatments and contained many genes linked to alcohol consumption. This substantiates previous findings that PPARa activation modulates activity of dopamine cells (Melis et al., 2010) and further supports a role of dopamine in alcohol-drinking behavior.
Given the evidence that neuroimmune signaling contributes to alcohol consumption and dependence (for review see (Mayfield et al., 2013) ), these drugs might be expected to decrease alcohol consumption through their anti-inflammatory effects. However, our data do not support prominent neuroimmune regulation by PPAR agonists. Instead these drugs seem to be targeting neurons and affecting synaptic transmission since there are more genes preferentially expressed in neurons than expected by chance within the PPAR agonist-regulated gene-sets. Moreover, there was a lack of genes associated with microglia in the regulated gene-sets. However, one of the treatment-responsive modules in the amygdala (salmon) was also enriched with microglial, astrocytic and cytokine receptor signaling genes. Overall, the results from WGCNA corroborated the strong neuronal signature of PPAR agonists in the CNS. This neuronal signature was unexpected and represents a surprising and significant finding.
There are two published microarray analyses of brain gene expression after PPAR agonist treatment. First, Chikahisa and colleagues fed mice a beza diet and analyzed brain gene expression in the hypothalamus to assess the effects of PPAR activation on circadian rhythm (Chikahisa et al., 2008) . Several genes were commonly regulated by beza in their dataset and in our amygdala and PFC datasets, including Arpp21, Chmp4b, Crem, Psmc3ip and Dtnb. Second, Searcy and colleagues delivered pioglitazone, a PPARg agonist, to triple transgenic Tg mice (a line used to model Alzheimer's disease) and analyzed its effect on brain gene expression in the hippocampus (Searcy et al., 2012) . Despite many experimental differences between this study and ours, there are remarkable similarities in the gene expression profiles. The overlap between their top-table and ours was greater than expected by chance for all PPAR agonist treatments in the amygdala, especially tesa (p ¼ 9.5e-08), and for tesa treatment in the PFC (p ¼ 3.09e-05). This is consistent with the activity of tesa at PPARg (Table S6) . ORA of the Searcy dataset did not support an overall pioglitazonemediated suppression of inflammatory processes, which is consistent with our findings. Additionally, their dataset and ours both exhibit alterations in genes involved in glutamatergic signaling. Functional studies further support a role for PPPAR agonists in glutamatergic signaling. For example, pioglitazone reduced NMDA-mediated calcium currents in brain (Pancani et al., 2009) , and the antidepressant effects of pioglitazone (mentioned above) were enhanced by co-administration of MK-801, an NMDA receptor blocker, and reversed by administration of NMDA (SalehiSadaghiani et al., 2012) . Moreover, the partial rescue of scopolamine-induced memory impairment by pioglitazone in mice 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 was decreased by sub-effective doses of MK-801 and increased by NMDA (Almasi-Nasrabadi et al., 2012) .
An important consideration is whether PPAR agonists decrease alcohol consumption via central or peripheral PPAR activation. The effective treatments increase Adh1 and decrease Aldh2 mRNA in the liver. This combination of changes (at the level of enzyme activity) leads to a build-up of acetaldehyde which is protective against developing alcohol dependence. Therefore it's possible that the effects on the liver might contribute to the decreased alcohol consumption. However, Stopponi et al. (2011) found that a PPARg agonist did not affect blood alcohol levels and blockade of central PPARs abrogated the anti-alcohol drinking effects, establishing the importance of central PPARs in this effect. The blood brain barrier penetrance of PPAR agonists is not well-studied, so the amount of drug reaching the brain is unknown. However, even if PPAR agonists do not have a direct effect in brain (because of lack of penetration), the fact that PPAR agonists change behavior suggests that there must be some change in brain signaling induced by PPAR agonists, whether it is direct or indirect. Thus, results from this study are still helpful in defining gene targets in brain to manipulate addiction-like behaviors.
A remaining question is whether the effects on alcohol consumption are mediated by PPAR-dependent or -independent mechanisms. A comparison of wild-type endothelial cells and endothelial cells lacking PPARa showed that only 26% of differentially expressed genes were PPARa-dependent after 18 h of fenofibrate treatment (Araki et al., 2009 ). PPAR-independent mechanisms have also been implicated in other brain disorders. For example, inhibition of Cdk5 via a PPARg-independent pathway decreased tau phosphorylation, a mechanism implicated in the positive effects of PPARg agonists in Alzheimer's disease (Cho et al., 2013) . Evidence also points to a non-transcriptional (phosphorylation-mediated) interaction between PPARa and the nAChR that at least partly mediates PPARa agonist effects on nicotine dependence (Melis et al., 2010) . Experiments using PPAR subunit knock-out strategies are needed to determine if the effects of feno and tesa on alcohol-consumption are PPAR-dependent or -independent.
In conclusion, these results demonstrate that changes in alcohol drinking behavior in mice following PPAR agonist administration are accompanied by changes in expression of brain genes, including many of those previously linked with regulation of alcohol consumption. Some of the gene expression changes observed in all three tissues had not been previously implicated in PPAR action. The transcriptional changes in neurons were unexpected and may be important in the behavioral effects of PPAR agonists on ethanol consumption. GABAergic interneurons, neuropeptide systems and dopaminergic signaling pathways may play a role in decreased alcohol drinking since these pathways are important for alcohol action and are associated with the effective PPAR treatments but absent in the non-effective treatment. This is the first microarray analysis of the amygdala and PFC after administration of selective PPAR agonists and will help determine the pharmacogenomic processes by which PPAR agonists decrease alcohol consumption, a critical step if these agents have a future as therapeutics for alcohol dependence.
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